TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30942962

Group type: COMPARATOR
Intervention: 67% w/w NaHCO3 toothpaste
Number of subjects: 56

Group type: COMPARATOR
Intervention: 0% w/w NaHCO3 toothpaste
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 20% w/w NaHCO3 toothpaste
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 35% w/w NaHCO3 toothpaste
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 50% w/w NaHCO3 toothpaste
Number of subjects: 56
Study: 26675187

Group type: EXPERIMENTAL
Intervention: Academy coaching intervention
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study: 25461793

Group type: EXPERIMENTAL
Intervention: Work-related cognitive-behavioral therapy (WCBT) plus vocational services as usual (VSAU)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Vocational services as usual (VSAU)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Work-related cognitive-behavioral therapy (WCBT)
Number of subjects: 58
Study: 22427021

Group type: COMPARATOR
Intervention: Placebo cigarettes (Quest© brand)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Moderate nicotine content cigarettes
Number of subjects: 67
Study: 21034483

Group type: EXPERIMENTAL
Intervention: Integrative care pathway involving exercise, massage, acupuncture, and cognitive behavioral therapy.
Number of subjects: 0
Study: 18981506

Group type: EXPERIMENTAL
Intervention: Ceramic filters
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control (no ceramic filters)
Number of subjects: 115
Study: 15803929

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (IVCY)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose IVCY induction followed by AZA maintenance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose IVCY induction followed by AZA maintenance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term oral CY induction followed by AZA maintenance
Number of subjects: 0
Study: 12160098

Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol (0.62 g/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Reinforcement (reward for performance)
Number of subjects: 48
Study: 10212739

Group type: EXPERIMENTAL
Intervention: New Religious Movements (NRMs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deluded psychotic in-patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups (non-religious and Christian)
Number of subjects: 0
Study: 8682918

Group type: EXPERIMENTAL
Intervention: Teeth with endodontic infection
Number of subjects: 133

Group type: COMPARATOR
Intervention: Teeth without endodontic infection or subsiding endodontic involvement
Number of subjects: 133
Study: 2223892

Group type: EXPERIMENTAL
Intervention: Paced respiration (10 minutes of slow-breathing training)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Attention control (counting pacing tones)
Number of subjects: 36
Study: 667244

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide (10 mg and 20 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg and 300 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo and 'no-drug' treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: White noise condition
Number of subjects: 24
Study: 31845065

Group type: EXPERIMENTAL
Intervention: Topiroxostat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 0
Study: 31093801

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral program for anxiety and social deficits
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 27494342

Group type: EXPERIMENTAL
Intervention: Upright posture with physiotherapy tape
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual posture with physiotherapy tape
Number of subjects: 61
Study: 26525008

Group type: EXPERIMENTAL
Intervention: Solobond M + Grandio
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Syntac + Tetric Ceram
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Molar restorations
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall restorations
Number of subjects: 30
Study: 26158178

Group type: EXPERIMENTAL
Intervention: Combined general/epidural anesthesia
Number of subjects: 71

Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 71
Study: 23071718

Group type: EXPERIMENTAL
Intervention: 25% caloric restriction (CR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 40
Study: 18927148

Group type: EXPERIMENTAL
Intervention: Home oxygen therapy with support from 'hospital in the home' (HiTH)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Traditional inpatient hospitalisation
Number of subjects: 44
Study: 17888067

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 68

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 68
Study: 14999696

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at a dose of 13 to 15 mg/kg/d for 2 years
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 12111084

Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Walking program (3 times per week, starting with 10-min duration)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 9260729

Group type: EXPERIMENTAL
Intervention: Aptiganel hydrochloride (CNS 1102) infused over 4 hours at doses of 15, 32, 50, or 73 microg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aptiganel hydrochloride (CNS 1102) at total doses of 32 microg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Higher doses of Aptiganel hydrochloride (CNS 1102)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aptiganel hydrochloride (CNS 1102)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aptiganel hydrochloride (CNS 1102) at total doses of up to 32 microg/kg infused over 4 hours
Number of subjects: 20
Study: 8240471

Group type: EXPERIMENTAL
Intervention: Reinforced laryngeal mask airway
Number of subjects: 104

Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 104
Study: 3481040

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX) 1000 mg/m2 iv over 24 hours weekly for 3 weeks, then every 6 weeks for 72 weeks, combined with low-dose 6-mercaptopurine (6MP; 50 mg/m2 orally per day) and methotrexate (MTX; 25 mg/m2 orally per week)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 108
Study: 30770262

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 424
Study: 29336182

Group type: EXPERIMENTAL
Intervention: Fermented milk containing Lactococcus lactis subsp. cremoris FC
Number of subjects: 31

Group type: COMPARATOR
Intervention: Non-fermented gelled milk (placebo)
Number of subjects: 31
Study: 27462096

Group type: EXPERIMENTAL
Intervention: Caregiver-delivered nurse-organized service programs
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 200
Study: 24665163

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 300mg orally once daily for 3 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no ALA supplementation)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (ALA supplementation)
Number of subjects: 80
Study: 22569899

Group type: EXPERIMENTAL
Intervention: Cangrelor + Clopidogrel
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo + Clopidogrel
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 234
Study: 20569031

Group type: EXPERIMENTAL
Intervention: Aloe vera cream
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 49
Study: 17907231

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 63
Study: 16159849

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 14293

Group type: COMPARATOR
Intervention: PCI
Number of subjects: 14293
Study: 12605586

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (0.56 g x day(‐1) x kg(‐1))
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 17
Study: 10952476

Group type: COMPARATOR
Intervention: MS Contin tablets (MSC)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Controlled-release morphine sulphate suppository (MSR)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: MSR
Number of subjects: 25

Group type: COMPARATOR
Intervention: MSC
Number of subjects: 25
Study: 8975964

Group type: EXPERIMENTAL
Intervention: α-interferon treatment
Number of subjects: 2927
Study: 1547765

Group type: EXPERIMENTAL
Intervention: Nifedipine (NFD) 20 mg b.i.d. for 4 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nifedipine (NFD) 40 mg b.i.d. for 4 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nifedipine (NFD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 2416190

Group type: EXPERIMENTAL
Intervention: Active hemodialysis
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 11
Study: 3113957

Group type: EXPERIMENTAL
Intervention: Metoprolol plus intravenous nitroglycerin (Group 2)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Metoprolol alone (Group 1)
Number of subjects: 14
Study: 31797407

Group type: EXPERIMENTAL
Intervention: Base-in prism
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 30894423

Group type: EXPERIMENTAL
Intervention: Robot assistant
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nurse
Number of subjects: 42
Study: 28933582

Group type: EXPERIMENTAL
Intervention: Rohto® Hydra (0.01% menthol)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Systane® Ultra treatments
Number of subjects: 48
Study: 24993741

Group type: EXPERIMENTAL
Intervention: Triple eradication treatment for H. pylori
Number of subjects: 370
Study: 23525529

Group type: EXPERIMENTAL
Intervention: Ultrafiltration group (n = 100)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (n = 50)
Number of subjects: 150
Study: 21561619

Group type: EXPERIMENTAL
Intervention: 23 gauge Quincke needle
Number of subjects: 53

Group type: COMPARATOR
Intervention: 25 gauge Quincke needle
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study: 19447597

Group type: EXPERIMENTAL
Intervention: Epidural clonidine and neostigmine (500 microg neostigmine and 75 microg clonidine)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (plain saline)
Number of subjects: 70
Study: 16847013

Group type: EXPERIMENTAL
Intervention: Immediate antibiotics (chloramphenicol eye drops; n = 104)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Delayed antibiotics (n = 109)
Number of subjects: 307

Group type: COMPARATOR
Intervention: No antibiotics (controls; n = 94)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Immediate antibiotics (n = 104)
Number of subjects: 307
Study: 15193674

Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg twice daily for six months
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 700
Study: 10960931

Group type: EXPERIMENTAL
Intervention: 5-FU and its modulation (specific agent, dose, and route not detailed)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Quality of life assessment at randomization and weeks 6, 11, and 21 post-randomization
Number of subjects: 279
Study: 9316554

Group type: EXPERIMENTAL
Intervention: High-dose hepatitis B vaccine (40 micrograms at 0, 1, 2, and 6 months)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard-dose hepatitis B vaccine (20 micrograms at 0.1, and 6 months)
Number of subjects: 110
Study: 8403467

Group type: EXPERIMENTAL
Intervention: Topical n‐6 essential fatty acids (evening primrose oil) added to 0.1% betamethasone valerate
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate twice daily for 3 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study: 3744133

Group type: COMPARATOR
Intervention: Intravenous unfractionated heparin (UFH) 240 anti‐Xa U/kg/12 h
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin Fragmin 240 anti‐Xa U/kg/12 h
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin Fragmin 120 anti‐Xa U/kg/12 h
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Subcutaneous Fragmin 120 anti‐Xa U/kg 2 times daily
Number of subjects: 54
Study: 29846739

Group type: EXPERIMENTAL
Intervention: Problem Solving Inventory (PSI)
Number of subjects: 78
Study: 26947719

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (up to 300 units), administered subcutaneously, two injections 12 weeks apart.
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo, administered subcutaneously, two injections 12 weeks apart.
Number of subjects: 152
Study: 24401022

Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus chlorambucil
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Rituximab plus chlorambucil
Number of subjects: 781

Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus chlorambucil vs. Rituximab plus chlorambucil
Number of subjects: 781
Study: 22874517

Group type: EXPERIMENTAL
Intervention: LPVr/ZDV/3TC
Number of subjects: 50

Group type: COMPARATOR
Intervention: LPVr/NVP
Number of subjects: 50
Study: 20555135

Group type: EXPERIMENTAL
Intervention: Galantamine treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 21
Study: 18507107

Group type: EXPERIMENTAL
Intervention: suspension-emulsion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: emulsion with a 7:3 mixture of lipiodol and contrast medium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: suspension
Number of subjects: 60
Study: 16430010

Group type: EXPERIMENTAL
Intervention: iBond
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Adper Prompt L‐Pop
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Xeno III
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Tyrian SPE + One Step Plus
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: One‐Up Bond F
Number of subjects: 33

Group type: COMPARATOR
Intervention: AdheSE
Number of subjects: 33

Group type: COMPARATOR
Intervention: Optibond Solo Plus
Number of subjects: 33

Group type: COMPARATOR
Intervention: Adper Scotchbond 1
Number of subjects: 33

Group type: COMPARATOR
Intervention: Optibond Solo Plus self‐etching
Number of subjects: 33

Group type: COMPARATOR
Intervention: Clearfil SE Bond
Number of subjects: 33

Group type: COMPARATOR
Intervention: Adper Scotchbond MP
Number of subjects: 33
Study: 12816878

Group type: EXPERIMENTAL
Intervention: 4 egg yolks daily
Number of subjects: 197

Group type: COMPARATOR
Intervention: 2 egg yolks daily
Number of subjects: 197
Study: 10360660

Group type: EXPERIMENTAL
Intervention: Paclitaxel 135 mg m(‐2) by 24‐h intravenous infusion + cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel 250 mg m(‐2) by 24‐h intravenous infusion + cisplatin + granulocyte colony‐stimulating factor (G‐CSF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel 135 mg m(‐2) + cisplatin administered as an outpatient by 3‐h infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etoposide/cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paclitaxel/cisplatin compared with historical controls treated with best supportive care
Number of subjects: 0
Study: 7741793

Group type: EXPERIMENTAL
Intervention: Spleno-peptides (SPS 1187, Solcosplen)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Transdermal estrogen (E2) substitution (4 mg)
Number of subjects: 256
Study: 2126836

Group type: EXPERIMENTAL
Intervention: Erdosteine (300 mg 3 times daily for 2 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7296520

Group type: EXPERIMENTAL
Intervention: Investigation to rule out non-bronchial primary adenocarcinomas
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Non-bronchial tumor investigation
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Comprehensive investigation methods
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Completion of investigations
Number of subjects: 87
Study: 31739120

Group type: EXPERIMENTAL
Intervention: 10% povidone‐iodine at 25 °C
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: 10% povidone‐iodine at 37 °C (warm PI)
Number of subjects: 220

Group type: COMPARATOR
Intervention: 4% chlorhexidine gluconate with alcohol at 25 °C
Number of subjects: 220

Group type: COMPARATOR
Intervention: 4% chlorhexidine gluconate with alcohol at 37 °C (warm CH)
Number of subjects: 220
Study: 29420589

Group type: EXPERIMENTAL
Intervention: Switching bipolar radiofrequency ablation (SB-RFA) using internally cooled-wet electrodes
Number of subjects: 69

Group type: COMPARATOR
Intervention: Switching monopolar radiofrequency ablation (SM-RFA) using separable clustered electrodes
Number of subjects: 69
Study: 27064975

Group type: COMPARATOR
Intervention: IM20 × 3 (3 intramuscular standard-dose injections of 20-μg at weeks 0, 4, and 24)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: IM40 × 4 (4 intramuscular double-dose injections of 40-μg at weeks 0, 4, 8, and 24)
Number of subjects: 437

Group type: COMPARATOR
Intervention: ID4 × 4 (4 intradermal low-dose injections of 4-μg at weeks 0, 4, 8, and 24)
Number of subjects: 437
Study: 24806825

Group type: EXPERIMENTAL
Intervention: Outdoor mobility rehabilitation programme delivered by 29 NHS therapists for up to 12 sessions over 4 months.
Number of subjects: 568

Group type: COMPARATOR
Intervention: Control group received verbal advice and transport and outdoor mobility leaflets prior to randomisation.
Number of subjects: 568
Study: 22301477

Group type: EXPERIMENTAL
Intervention: TDF 300 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 20584070

Group type: EXPERIMENTAL
Intervention: telmisartan at 80 mg day(‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: enalapril at 10 mg day(‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both telmisartan and enalapril
Number of subjects: 30
Study: 17675590

Group type: EXPERIMENTAL
Intervention: BKB-SIN
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: HINT
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: QuickSIN
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: WIN
Number of subjects: 96
Study: 15715914

Group type: EXPERIMENTAL
Intervention: Education and Activation Programme (EAP) in addition to usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study: 12401533

Group type: EXPERIMENTAL
Intervention: Compliance with Step II dietary goals (≤30% of total calories from fat, <7% of calories from saturated fat, daily dietary cholesterol <200 mg)
Number of subjects: 13777

Group type: EXPERIMENTAL
Intervention: Having a college degree
Number of subjects: 13777

Group type: EXPERIMENTAL
Intervention: Prior cardiovascular event
Number of subjects: 13777

Group type: EXPERIMENTAL
Intervention: Consumption of five or more daily servings of fruits or vegetables
Number of subjects: 13777

Group type: COMPARATOR
Intervention: Being married, smoking, a sedentary lifestyle, and a higher body mass index
Number of subjects: 13777

Group type: EXPERIMENTAL
Intervention: Dietary compliance
Number of subjects: 13777
Study: 10099039

Group type: EXPERIMENTAL
Intervention: 5.0 mg/d isradipine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 7.5 mg/d isradipine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 10.0 mg/d isradipine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 7858046

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 49
Study: 2574049

Group type: EXPERIMENTAL
Intervention: xamoterol (200 mg twice a day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study: 29469638

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27423381

Group type: EXPERIMENTAL
Intervention: miRNA expression profiling (miScript miRNA PCR Array)
Number of subjects: 41
Study: 24977688

Group type: COMPARATOR
Intervention: Modified ultrafiltration for 10 minutes (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration for 15 minutes (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration for 20 minutes (Group 3)
Number of subjects: 60
Study: 22315014

Group type: EXPERIMENTAL
Intervention: Weight loss therapy
Number of subjects: 40
Study: 20049572

Group type: EXPERIMENTAL
Intervention: Continuous intraarticular infusion with 300 mL ropivacaine 0.2% at a speed of 5 mL/hour
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline solution at an infusion speed of 5 mL/hour (Control)
Number of subjects: 50
Study: 17761020

Group type: EXPERIMENTAL
Intervention: Whole-grain wheat (WG)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Wheat bran (WB)
Number of subjects: 31
Study: 15795204

Group type: EXPERIMENTAL
Intervention: Internal fixation with cannulated screws
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hemiarthroplasty using an uncemented Austin Moore prosthesis
Number of subjects: 60
Study: 12508961

Group type: EXPERIMENTAL
Intervention: Doxazosin (2-4 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Amlodipine (5-10 mg/day)
Number of subjects: 15
Study: 9439220

Group type: EXPERIMENTAL
Intervention: Follow-on formula
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 100
Study: 1659975

Group type: EXPERIMENTAL
Intervention: Temafloxacin (600 mg)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 131
Study: 6790805

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of nitroglycerin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no nitroglycerin)
Number of subjects: 60